4 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer Docetaxel intermittent - Castration Resistant Prostatic Cancer | Phase 2 | Terminated | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 6 | 2022-07-29 | 2024-11-22 |
| A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer BMS-986218, Docetaxel, Nivolumab - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Terminated | Bristol-Myers Squibb | 10 | 2022-02-14 | 2025-06-10 |
| Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) Darolutamide (Nubeqa, BAY1841788), Enzalutamide - Prostatic Cancer, Castration-Resistant | Phase 2 | Terminated | Bayer | 30 | 2019-12-17 | 2023-08-04 |
Anus Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Small Cell (1) · Melanoma (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Prostatic Neoplasms (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Anus Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1)
enzalutamide (2) · Docetaxel (1) · Nivolumab (1) · abiraterone (1) · darolutamide (1)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Bayer (1) · Bristol-Myers Squibb (1) · MacroGenics (1)
United States (3) · Australia (2) · France (2) · Italy (2) · Belgium (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Kate Mahon (1) · Liudmila Schafer, M.D. (1)